At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 10 target
Drug / intervention
NBQ72Sdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa Study to Evaluate the Efficacy and Safety of NBQ72S in Breast Cancer Patients With Leptomeningeal Metastases, With or Without Brain Parenchymal Metastases
Nantong Bencao Quadriga Medical Technology Co. Ltd.·interventional·Posted Feb 6, 2025·Updated Apr 13, 2026
In Brief
A Phase 2 clinical trial evaluating NBQ72S for Breast Cancer. Currently recruiting, targeting 10 participants across 1 site.
Detailed Summary
A phase IIa, single-arm, open-label study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer. All patients will receive the study drug every 28 days until withdrawal from treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
202520262027
First PostedFeb 2025
Enrollment StartApr 2025
TodayJul 2026
Primary CompletionAug 2026
Study CompletionFeb 2027
First PostedFeb 6, 2025
Enrollment StartApr 22, 2025
Primary CompletionAug 31, 2026
Study CompletionFeb 28, 2027
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 1.4 years agoPrimary completion in 2 months
Interventions
NBQ72Sdrug
Patients will receive the study drug every 28 days